Delenex Therapeutics Complements its Management

Delenex appoints Eric de La Fortelle as CEO and Jakob Schlapbach as CFO

07-Feb-2011 - Switzerland

Delenex Therapeutics announced the appointments of Eric de La Fortelle as new CEO, and Jakob Schlapbach as new CFO.

Eric de La Fortelle brings significant experience from the pharmaceutical industry to Delenex. He served previously in two senior roles at F. Hoffmann-La Roche ("Roche"). Beginning in 2005, Eric was Global Head, External Research and Technologies, leading a ten-person group responsible for establishing and managing around fifty strategic alliances each year in early-stage products and technologies. In 2008 and 2009, he also served as Global Head, Emerging Technologies.

Eric de La Fortelle's scientific work contributed to the field of protein structure determination. The SHARP software, of which he was the initial lead author, contributed to the resolution of more than a thousand protein structures by X-ray crystallography.

Eric de La Fortelle is a graduate from Ecole Centrale de Paris, holds a Ph.D. in structural biology from Paris XI University and an MBA from INSEAD.

Jakob Schlapbach joined Delenex in December, 2010, as CFO. Mr. Schlapbach brings more than thirty years of banking and industrial financing experience to the company. He has been CFO of Cytos Biotechnology for more than ten years until mid-2010 and hold the same position with Ascom group between 1994 and 2000. At Cytos Biotechnology he has been instrumental in raising funds in the amount of CHF 262 million from institutional and private investors and played a key role in the going public of Cytos Biotechnology. He was elected "CFO of the Year" in 2002 by the renowned Swiss newspaper Finanz und Wirtschaft.

Jakob Schlapbach holds an MBA from INSEAD and an economics degree from University of Berne (lic.rer.pol.).

https://www.bionity.com/en/news/130666/delenex-therapeutics-complements-its-management.html